Table 3 Kinase-inhibitors in soft tissue sarcomas: prospective evidence
From: Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new
Study | Population | Study phase | Drug and schedule | Patients | Overall response rate (%) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|---|
Tyrosine-kinase inhibitors | |||||||
George et al., 2009 [60] | Metastatic all-type STS | Phase II | Sunitinib 37.5 mg once daily | 53 | 2 | 1.8 | NA |
Hensley et al., 2009 [59] | Advanced uterine LMS | Phase II | Sunitinib 50 mg daily, 4 weeks on, 2 weeks off | 25 | 9 | 1.5 | NA |
Rutkowski et al., 2010 [19] | DFSP | Pooled analysis of two phase II | Imatinib 400–800 mg daily | 34 | 32 | 20.4 | Unreached |
Wagner et al., 2012 [68] | MTF-associated tumours (including ASPS, CCS) | Phase II | Tivantinib 120 mg, twice daily | 47 | 2 | 3.6 | NA |
van der Graaf et al., 2012 [45] | Metastatic, non-adipocytic STS | Randomised, phase III | Arm A: pazopanib 800 mg daily Arm B: placebo | Arm A: 246 Arm B: 123 | Arm A: 6 Arm B: 0 | Arm A: 4.6 Arm B: 1.6 | Arm A: 12.5 Arm B: 10.7 |
Ray-Coquard et al., 2012 [55] | Advanced superficial (stratum A) and visceral (stratum B) angiosarcoma | Phase II | Sorafenib 400 mg twice daily | Stratum A: 26 Stratum B: 15 | Stratum A: 15 Stratum B: 13 | Stratum A: 1.8 Stratum B: 3.8 | Stratum A: 12 Stratum B: 9 |
Kummar et al., 2013 [61] | Advanced ASPS | Phase II | Cedinarib 30 mg daily | 46 | 35 | Â | Â |
Mir et al., 2016 [54] | Cohort A: LPS Cohort B: LMS Cohort C: SS Cohort D: other sarcomas | Randomised, phase II | Arm A: regorafenib 160 mg/day 3 weeks on, 1 week off Arm B: placebo | Cohort A: 43 Cohort B: 56 Cohort C: 27 Cohort D: 56 | Cohort A: 0 (arm A) vs. 0 (arm B) Cohort B: 0 (arm A) vs. 4 (arm B) Cohort C: 8 (arm A) vs. 0 (arm B) Cohort D: 11 (arm A) vs. 0 (arm B) | Cohort A: 1.1 (arm A) vs. 1.7 (arm B) Cohort B: 3.7 (arm A) vs. 1.8 (arm B) Cohort C: 5.6 (arm A) vs. 1 (arm B) Cohort D: 2.9 (arm A) vs. 1 (arm B) | Cohort A: 4.7 (arm A) vs. 8.8 (arm B) Cohort B: 21 (arm A) vs. 9.1 (arm B) Cohort C: 13.4 (arm A) vs. 6.7 (arm B) Cohort D: 12.1 (arm A) vs. 9.5 (arm B) |
Chi et al., 2016 [62] | Metastatic all-type STS | Phase II | Anlotinib 12 mg daily, 2 weeks on, 1 week off | 166 | 11 | 5.6 | NA |
Agulnik et al., 2016 [87] | Metastatic all-type STS | Phase II | Tivozanib 1.5Â mg daily, 3 week on, 1 week off | 58 | 3.6 | 3.5 | 12.2 |
Schuetze et al., 2016 [67] | Metastatic all-type STS | Phase II | Dasatinib 100 mg twice daily | 200 | 1 | 1.9 | 8 |
Schuetze et al., 2017 [66] | Metastatic ASPS, CS, chordoma, ES, SFT | Phase II | Dasatinib 100 mg twice daily | 116 | <1 | 5.8 | 21.6 |
Serine/threonine kinase inhibitors | |||||||
Demetri et al., 2013 [69] | Metastatic all-type STS and BS (responsive/stable on CHT) | Randomised, phase III | Arm A: ridaforolimus 40 mg once daily, 5 days every week Arm B: placebo | Arm A: 347 Arm B: 364 | NA | Arm A: 17.7 Arm B: 14.6 | Arm A: 21 Arm B: 19.8 |
Schwartz et al., 2013 [76] | Metastatic all-type STS and BS | Phase II | Cixutumumab (6 mg/kg) and temsirolimus (25 mg) | 174 | 5 | NA | NA |
Dickson et al., 2013 [80] | Advanced CDK4-amplified WDLPS/DDLPS | Phase II | PD0332991 200 mg orally once daily, 2 weeks on, 1 week off | 30 | 3 | 18 | NA |